US 12,169,202 B2
Measurement of 2-hydroxyglutarate enantiomer levels as a biomarker for IDH mutant cancers
Mark R. Emmett, Galveston, TX (US); Shinji K. Strain, Texas City, TX (US); and Morris D. Groves, West Lake Hills, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Feb. 10, 2021, as Appl. No. 17/172,940.
Claims priority of provisional application 62/975,609, filed on Feb. 12, 2020.
Prior Publication US 2021/0263037 A1, Aug. 26, 2021
Int. Cl. G01N 33/48 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/57488 (2013.01) 4 Claims
 
1. A method of identifying 2-hydroxygluterate (2-hg) metabolites in a sample comprising:
a) obtaining the sample from a patient, wherein the biological fluid is selected from at least one of: serum, urine, cerebrospinal fluid, or sputum;
b) extracting the 2-hydroxygluterate (2-hg) metabolites from the sample;
c) derivatizing the 2-hydroxygluterate (2-hg) metabolites with trimethylsilyldiazomethane (TMSDAM) and methanol;
d) separating the one or more 2-hg metabolites in the sample using a chiral gas chromatography capillary column; and
e) quantitating an amount of 2-hg metabolites and enantiomers in the sample using mass spectrometry (MS).